RA Patients Successfully Discontinue Prednisolone After 7 Weeks, Study Finds

For individuals newly diagnosed with rheumatoid arthritis (RA), a rapid taper off the corticosteroid prednisolone appears to be not only possible but highly achievable, according to research published in the Annals of the Rheumatic Diseases. The findings challenge some existing guidelines and offer a potential pathway to minimize the long-term side effects associated with prolonged steroid use.

Bridging the Gap: Steroid Use in Early RA Management

Rheumatoid arthritis is a chronic autoimmune disease causing inflammation of the joints, leading to pain, swelling, and eventual joint damage. Treatment typically involves disease-modifying antirheumatic drugs (DMARDs), like methotrexate, to suppress the immune system and slow disease progression. Although, DMARDs can accept weeks or months to turn into fully effective. Prednisolone, a potent corticosteroid, is often used as a “bridge” to provide rapid symptom relief while waiting for the DMARDs to work. The debate centers on how long this bridge should be, and whether the potential benefits outweigh the risks of long-term steroid exposure.

Gina Hetland Brinkmann, MD, of Diakonhjemmet Hospital in Oslo, Norway, explained that the study was motivated by differing international recommendations. While the European League Against Rheumatism (EULAR) suggests low-dose glucocorticoids as a bridging therapy, the 2021 American College of Rheumatology guidelines advise against their use due to concerns about toxicity and the perceived difficulty of weaning patients off steroids. EULAR recommends a cautious approach, but the ACR guidelines lean towards avoiding steroids altogether in early RA management.

Study Design and Key Findings

Brinkmann and colleagues conducted a follow-up analysis of 227 patients from the ARCTIC trial, all with recent-onset RA who had not previously been treated with DMARDs. Participants began treatment with methotrexate alongside a prednisolone bridging regimen, with the steroid dose gradually reduced from 15mg to 0mg daily over a 7-week period. The researchers then tracked the patients for 24 months to assess their ability to discontinue prednisolone and maintain disease control.

The results were encouraging. A significant 84% of patients successfully stopped taking prednisolone by 7 weeks. This success rate increased to 89% at 3 months and reached 95% by the 24-month mark. Importantly, 80% of those who discontinued prednisolone at 7 weeks did not restart it. The average age of participants was 52, and the majority (62%) were women. A substantial 82% tested positive for anticitrullinated peptide antibodies, a marker often associated with more aggressive RA.

The median duration of prednisolone use across the entire cohort over the two-year follow-up was 55 days (with an interquartile range of 48-90 days). While a little percentage (5%) continued to use prednisolone at every visit, 22% used it continuously for at least three months, suggesting some patients required ongoing, albeit limited, steroid support.

What Does This Mean for Patients?

These findings suggest that a structured, 7-week prednisolone taper is a feasible strategy for managing early RA. This represents particularly relevant given the potential for significant side effects associated with long-term corticosteroid use, including weight gain, increased risk of infection, osteoporosis, and cardiovascular problems. Glucocorticoid toxicity remains a significant concern for clinicians.

However, it’s crucial to understand that this study focused on patients initiating treatment with methotrexate under a “treat-to-target” strategy – meaning their treatment was proactively adjusted to achieve remission or low disease activity. The success of this approach likely depends on close monitoring and timely escalation of DMARD therapy if needed. This isn’t a “one-size-fits-all” solution, and individual responses to treatment can vary.

Understanding the Evidence: Trial Design and Limitations

The ARCTIC trial, from which these data were derived, provides a robust foundation for these conclusions. However, it’s important to acknowledge the study’s limitations. The cohort was relatively homogenous, consisting primarily of patients initiating methotrexate therapy. The findings may not be generalizable to individuals with more severe RA, those requiring combination DMARD therapy, or those with contraindications to methotrexate. The study focused on the ability to discontinue prednisolone, but did not specifically assess long-term disease activity or structural joint damage.

The study also doesn’t address the optimal strategy for patients who *do* require continued prednisolone use. The 22% who used the drug for at least three months may represent a subgroup with more challenging disease or a slower response to DMARDs. Further research is needed to identify factors predicting which patients are most likely to benefit from a prolonged, low-dose steroid regimen.

The Role of Glucocorticoids in Infection

The timing of these findings is particularly relevant given ongoing research into the interplay between glucocorticoids and infection risk. Recent studies have highlighted the potential for glucocorticoids to suppress the immune system and increase susceptibility to opportunistic infections. Glucocorticoids in the Setting of Active Infection is an area of active investigation, and clinicians must carefully weigh the risks and benefits of steroid use in patients with known or suspected infections.

What Comes Next: Refining Treatment Strategies

Brinkmann and colleagues emphasize that their findings support the EULAR strategy of short-term bridging with glucocorticoids, combined with a strict treat-to-target DMARD protocol. Implementing standardized tapering protocols and proactively escalating DMARD therapy when needed may help clinicians achieve rapid symptom control while minimizing the risk of long-term glucocorticoid toxicity. Further research is needed to identify biomarkers that can predict which patients are most likely to successfully taper off steroids and to optimize treatment strategies for those who require ongoing support. The ongoing debate surrounding steroid use in early RA underscores the importance of individualized treatment plans and shared decision-making between patients and their healthcare providers.

Gina Hetland Brinkmann, MD, can be contacted at [email protected].